Please Wait
Applying Filters...
menu
    • menu
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    Heparin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,056Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    28/10/2024 HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.
    China
    		 HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD. Shijiazhuang CN CEP 2005-270 - Rev 12 Heparin sodium 2024-03-01 Valid Chemical 333
    28/10/2024 Leo Pharma
    Denmark
    		 LEO PHARMA A/S Ballerup DK R1-CEP 2001-446 - Rev 03 Heparin sodium, For parenteral preparations, European and Chilean origin 2020-02-21 Valid Chemical 333